ECB Calls for Monitoring and Possible Regulation of AI in Finance 
Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
The 2023 Sir Paul Curran award for academic journalism goes to Barbara Sahakian 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
Skepta and PUMA Launch Groundbreaking Collection 
Green industry yes, conservation no: a budget for people, not for nature 
How supermarkets are changing their branding to make you think they’re cheaper 
McDonald's Faces Backlash Over $5 Meal Deal: Customers Call It 'Skimpy' 
McDonald's Philippines Launches 'Ride the Arches' for Cyclists 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
Burger King’s Largest Franchisee Carrols, Acquired by RBI for $1 Billion, $500M Revamp 
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 13, 2018 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that Bruce Cousins, Executive Vice President and Chief Financial Officer, is leaving the Company but will remain available on a consulting basis. Koert VandenEnden, Arbutus’ Vice President of Finance, will serve as Interim Chief Financial Officer. The Company will promptly begin a search for a permanent Chief Financial Officer.
"We would like to thank Bruce for his dedicated service to Arbutus over the past 4 years and wish him the very best in his professional endeavors," said Dr. Mark J. Murray, Arbutus' President and CEO. “Having recently completed the $116mm financing with Roivant Sciences the Company’s balance sheet is strong and the Company has recently announced the consolidation of the business to Warminster, PA, both of which represent important factors in this decision.”
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Mark Murray
President and Chief Executive Officer
Phone: 604-419-3200
Email: [email protected]
Tiffany Tolmie
Manager, Investor Relations
Phone: 604-419-3200
Email: [email protected]
Media
David Schull
Russo Partners
Phone: 858-717-2310
Email: [email protected]
